Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Accelerating SuFEx Reactions via Aryl Fluorosulfate Structural Engineering for Enhanced Covalent Targeted Cancer Therapy.

Angewandte Chemie (International ed. in English)·2026
Same author

PRGNet: a Parallel Residual Graph Network for enhanced drug-target binding affinity prediction.

BMC genomics·2026
Same author

Sequential transcriptional waves and NF-κB-driven chromatin remodeling direct drug-induced dedifferentiation in cancer.

Nature communications·2026
Same author

Programmable divergent electrochemical ring-opening multifunctionalization of strained rings.

Nature chemistry·2026
Same author

Electrooxidative C-C Fragmentation of Aromatic Radical Cations for Cascade Benzylic Multifunctionalization.

Angewandte Chemie (International ed. in English)·2026
Same author

KGBN: Augmenting and optimizing logical gene regulatory networks using knowledge graphs.

bioRxiv : the preprint server for biology·2026

Related Experiment Video

Updated: Dec 21, 2025

Author Spotlight: Unlocking Insights into the Immune Cell Landscape of Tumors
06:32

Author Spotlight: Unlocking Insights into the Immune Cell Landscape of Tumors

Published on: August 18, 2023

2.7K

Intrinsic Genetic and Transcriptomic Patterns Reflect Tumor Immune Subtypes Facilitating Exploring Possible

Yong Xu1,2, Daixi Li1, Zhenhao Liu2

  • 1Laboratory for Computational Biology, University of Shanghai for Science and Technology, Shanghai, China.

Frontiers in Molecular Biosciences
|May 12, 2020
PubMed
Summary

This study links breast cancer immune subtypes to genetic mutations and gene expression. Findings reveal potential drug targets and combinations for personalized therapy based on immune profiles.

Keywords:
breast invasive carcinomacombination therapyimmune subtypessignaling pathwaystarget

More Related Videos

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.4K
Enrichment and Characterization of the Tumor Immune and Non-immune Microenvironments in Established Subcutaneous Murine Tumors
08:32

Enrichment and Characterization of the Tumor Immune and Non-immune Microenvironments in Established Subcutaneous Murine Tumors

Published on: June 7, 2018

10.1K

Related Experiment Videos

Last Updated: Dec 21, 2025

Author Spotlight: Unlocking Insights into the Immune Cell Landscape of Tumors
06:32

Author Spotlight: Unlocking Insights into the Immune Cell Landscape of Tumors

Published on: August 18, 2023

2.7K
Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.4K
Enrichment and Characterization of the Tumor Immune and Non-immune Microenvironments in Established Subcutaneous Murine Tumors
08:32

Enrichment and Characterization of the Tumor Immune and Non-immune Microenvironments in Established Subcutaneous Murine Tumors

Published on: June 7, 2018

10.1K

Area of Science:

  • Oncology
  • Immunology
  • Genomics
  • Transcriptomics

Background:

  • Immune subtypes are classified by tumor immune microenvironment signatures.
  • Association between immune subtypes, tumor mutation, and expression patterns is known.
  • Contribution of intrinsic genetic/transcriptomic alterations to immune subtypes and optimal drug combinations remain unclear.

Purpose of the Study:

  • To investigate the relationship between genetic and transcriptomic alterations and immune subtypes in breast invasive carcinoma (BRCA).
  • To identify potential drug targets and combination therapies for distinct immune subtypes.

Main Methods:

  • Statistical analysis of genetic alterations and transcriptional profiles from BRCA samples.
  • Analysis of somatic missense mutations, frameshift deletions, and DNA double-strand break repair pathway gene expression.
  • Extensive analysis of signaling pathways at genetic and transcriptomic levels.

Main Results:

  • Significant differences in somatic missense mutations and frameshift deletions were observed among immune subtypes.
  • High mutation load correlates with high expression of DNA double-strand break repair genes.
  • Altered pathways include Tumor Protein P53 (TP53) and Receptor Tyrosine Kinase (RTK)/RAS; specific subtypes show alterations in MAP3K1, PIK3CA, CDK4/6, and ERBB2.

Conclusions:

  • Intrinsic genetic and transcriptomic alterations are associated with distinct immune subtypes in BRCA.
  • Identified genetic alterations and pathway differences provide potential subtype-specific drug targets.
  • Functional pathway analysis suggests extrinsic factors influencing prognosis and potential combination therapies for different immune subtypes.